

« . . . » -
»

()

,
.
,
- 30 80%. [11,19,21,23].

ó

[16].

[3,4,13,21].

(, , ,)

).

(-, -, , ,) [2,13]

[1].

[17],

:

ó 47,7%,

ó 90,7%,

ó 32%

, ...

(

ó

§

ö,

).

(,),

5,7%

- 14,7%

- 33,4%, ...

[23],

- /

(

),

[5,22,18].

,

[6,

1,11,14,21].

. . . ,

,

.

[9]

[7], ,

,

.

()

.

:

- / ;
- - ;
- - ;
- -

.

,

,

- , -

,

[7]:

- () ó
ó , Ca⁺⁺
;
- () ó
E₂
;
- () ó
ó ,
;
- *NMDA* () ó
;
- () ó
-
.
-, -
1.
,
,
.
,
,
,
.
(,

).

1

					NMDA
3-5	150 /	—	—	—	—
	75	—	8	—	—
	—	—	—	20 000	0,5 /
	—	—	—	60 000 ()	0,5-0,7 / .
1-7 /	/ 225	12,5-25 /	—	30 000 (2-3 /)	0,05 / . (2-3 /)
2 . /	/ 150	12,5 /	—	—	—
3-5 . /	/ 150	—	—	—	—
6 6 . /	/ 75	—	—	—	—

53

(, ,
IIA-IIB),

28 ,

48±19 , 16, 12.
- 16, - 12 . 19 28

II ó III

ASA, . .
. 8 28 ,

(200±70 /)

(300 75
) ,

[14],

- () «0-4 » ;

- PAIN Detect [12], :

(, , , . . . ; -) PAIN Detect 28 , , .

[8,7]:

- I ó (): 0,04 / . , 0,7 / . , 0,0025 / . , N₂O 50-60%, ó 0,7 / . 60 000 .

- II - (L_{II}-L_{III}, 65±10,8) ; I (0,0012 / . , <0,05) (0,47 / . , , <0,05)

: 8 / ,
 (0,13/0,1 / /),
 / .
 /
 1 100 / .
 / 30 000 / 2-3 .
 +
 (0,2% 12-16 /),
)
 5-7 (Vogt Medical
 Microinfusion Pump,).
 0,05 / .
 (Asena Alaris GS,) 2-3 (. .1)
 .
 ,
 .1. , 1 /
 225/900 / ,
 6 ,
 [19].

), (- 14500 -
). Cell Saver.
 96^0 / 1%
 1:10.

($1,38 \pm 0,3$ $1,4 \pm 0,3$
 +),
 .
 1 + (2-
 3) 1- /
 0,1 / . , 3
 . « »
 , .
 / ,
 28 , 25.
 . « »
 (10 ó , 12 ó +)
 , (5/14) (3/14) « ».
 : «
 » (-3, -5), «
 » (2), « » (1).

10-12

, ...

«19-38

»,

>90%.

7-9

.

:

53

5

3

2

,

48

5

.

,

.

,

,

.

/

(

).

, ...

.

,

,

,

.

.

(

,

),

,

17. Probstner D., Thuler L.C.S., Ishikawa N.M., Alvarenga R.M.P. Phantom limb phenomena in cancer amputees. *Pain Practice* 2010; 10(3): 249-256.
18. Reuben S. Persistent postoperative pain: pharmacological treatment strategies in the postoperative setting, *Pain 2008 - an Updated Review*. Eds. Castro-Lopes J., Raja S., Scmelz M. IASP Press. Seattle 2008; 159-169.
19. Richardson C., Glenn S., Nurmikko T., Horgan M. Incidence of phantom phenomena including phantom limb pain 6 months after major lower limb amputation in patients with peripheral vascular disease. *Clin.J. Pain* 2006; 22: 353-358.
20. Rittner H.L., Stein Ch. Neuroimmune interactions in inflammatory pain. *Euroanaesthesia 2005*. Vienna Austria. Refresher Course Lectures. ESA 2005; 275-278.
21. Schug St. A., Pogatzki & Zahn E.M. Chronic pain after surgery or injury. *Pain Clinical Updates*. IASP. 2011 XIX; Issue 1: 1-5.
22. Sindrup S.H. Clinical pharmacology of antiepileptics and antidepressants in the management of neuropathic pain. *Pain 2008- an Updated Review*. Eds. Castro-Lopes J., Raja S., Schmelz M. IASP Press. Seattle 2008; 217-223.
23. Vadalouca A., Raptis E., Moka E., Zis P. et al. Pharmacological treatment of neuropathic cancer pain: a comparative review of the current literature. *Pain Practice* 2012; 12 (3): 219-151.